Source 1primary paper2026MED
Toolkit/LNP
LNP
Also known as: lipid nanoparticles
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Usefulness & Problems
Why this is useful
LNPs are discussed as emerging delivery vehicles for gene editing therapies in cardiovascular disease.; delivery of gene editing payloads; liver-targeted in vivo editing modalities
Source:
LNPs are discussed as emerging delivery vehicles for gene editing therapies in cardiovascular disease.
Source:
delivery of gene editing payloads
Source:
liver-targeted in vivo editing modalities
Problem solved
They address delivery of editing systems for in vivo therapeutic use, including liver-targeted modalities mentioned in the abstract.; provides a delivery vehicle for in vivo gene editing applications
Source:
They address delivery of editing systems for in vivo therapeutic use, including liver-targeted modalities mentioned in the abstract.
Source:
provides a delivery vehicle for in vivo gene editing applications
Problem links
provides a delivery vehicle for in vivo gene editing applications
LiteratureThey address delivery of editing systems for in vivo therapeutic use, including liver-targeted modalities mentioned in the abstract.
Source:
They address delivery of editing systems for in vivo therapeutic use, including liver-targeted modalities mentioned in the abstract.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Techniques
No technique tags yet.
Target processes
editingtranslationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: delivery
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Independent follow-up evidence is still limited. Validation breadth across biological contexts is still narrow. Independent reuse still looks limited, so the evidence base may be fragile. No canonical validation observations are stored yet, so context-specific performance remains under-specified.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
The review discusses AAVs, LNPs, lentivirus, and virus-like particles as emerging delivery vehicles for gene editing therapies targeting lipid metabolism in cardiovascular disease.
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Approval Evidence
1 source1 linked approval claimfirst-pass slug lnp
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Source:
delivery scopesupports
The review discusses AAVs, LNPs, lentivirus, and virus-like particles as emerging delivery vehicles for gene editing therapies targeting lipid metabolism in cardiovascular disease.
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Source:
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Source-backed strengths
Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed.
Compared with AAV-based viral vectors
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Source:
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Compared with Adeno-associated virus
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Source:
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Compared with lentivirus
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Source:
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Compared with lipid nanoparticles
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Source:
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Compared with mRNA-lipid nanoparticles
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Source:
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Compared with mRNA-loaded lipid nanoparticles
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Source:
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Compared with virus-like particles
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Source:
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Compared with virus-like particle vaccine platform
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Shared frame: source-stated alternative in extracted literature
Source:
The abstract contrasts LNPs with AAVs, lentivirus, and virus-like particles.
Ranked Citations
- 1.